SCHEMBL2914485

SCHEMBL2914485

Cc1cc2c(cc1Cl)C(=O)CC2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PBRM1 Q86U86 1/20 0.41
CASP1 P29466 1/20 0.41
CASP7 P55210 1/20 0.41
HSD17B10 Q99714 1/20 0.41
BRD4 O60885 1/20 0.40
TYMS P04818 1/20 0.39
GRIN2D O15399 1/20 0.38
GRIN3B O60391 1/20 0.38
GRIN1 Q05586 1/20 0.38
GRIN2A Q12879 1/20 0.38
GRIN2B Q13224 1/20 0.38
GRIN2C Q14957 1/20 0.38
GRIN3A Q8TCU5 1/20 0.38
PTGS2 P35354 4/20 0.38
PTGS1 P23219 3/20 0.38
HSD17B1 P14061 2/20 0.37
CD44 P16070 1/20 0.35
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
PRKCI P41743 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2907226 0.92 PBRM1 (0.41) PBRM1CASP1CASP7HSD17B10BRD4
SCHEMBL17546199 0.89 MAOA (0.44) BRD4GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL1273997 0.83 PBRM1 (0.47) PBRM1CASP1CASP7HSD17B10BRD4
SCHEMBL31591225 0.83 PBRM1 (0.47) PBRM1CASP1CASP7HSD17B10TYMS
SCHEMBL1512735 0.83 PBRM1 (0.47) PBRM1CASP1CASP7HSD17B10TYMS
SCHEMBL10102257 0.76 PBRM1 (0.50) PBRM1CASP1CASP7HSD17B10BRD4
SCHEMBL4818430 0.76 PBRM1 (0.41) PBRM1CASP1CASP7HSD17B10BRD4
SCHEMBL14430312 0.76 HSD17B1 (0.44) PBRM1CASP1CASP7HSD17B10PTGS2
SCHEMBL11980463 0.76 PBRM1 (0.41) PBRM1CASP1CASP7HSD17B10BRD4
SCHEMBL19887446 0.76 PBRM1 (0.41) PBRM1CASP1CASP7HSD17B10TYMS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130017149-A1 PHARMACEUTICAL COMPOUNDS NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) 2013-01-17 US disclosed
EP-2223914-A1 Tricyclic condensed pyrazole derivatives as CB1 inhibitors Neuroscienze Pharmaness S.C. A R.L. (IT) 2010-09-01 EP disclosed
EP-2223913-A1 Tricyclic pyrazole derivatives and microemulsions thereof as CB1- and/or CB2-inhibitors Neuroscienze Pharmaness S.C. A R.L. (IT) 2010-09-01 EP disclosed
US-20100215741-A1 PHARMACEUTICAL COMPOUNDS NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) 2010-08-26 US disclosed
US-20100216785-A1 PHARMACEUTICAL COMPOSITIONS NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) 2010-08-26 US disclosed
US-20090163559-A1 Estrogen receptor modulators MERCK SHARP & DOHME LLC 2009-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100215741-A1 PHARMACEUTICAL COMPOUNDS CNR1, CNR2, TRPV1 PBRM1 746/4885CASP1 2843/4885CASP7 3311/4885
US-20130017149-A1 PHARMACEUTICAL COMPOUNDS CNR1, CNR2, TRPV1 PBRM1 746/4885CASP1 2843/4885CASP7 3311/4885
US-20090163559-A1 Estrogen receptor modulators GPER1, ESR2, ESRRA PBRM1 2866/4885CASP1 3997/4885CASP7 4246/4885
US-20100216785-A1 PHARMACEUTICAL COMPOSITIONS CNR2, CNR1, SGMS2 PBRM1 2754/4885CASP1 3474/4885CASP7 2235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.